Peter Alping
Impact in
-
- Multiple Sclerosis Research Studies
-
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
Papers in
-
- Multiple Sclerosis Research Studies 12
-
- Pregnancy and Medication Impact 1
- Co-authors
- Fredrik Piehl (11 shared papers)Jan Lycke (6 shared papers)Katharina Fink (8 shared papers)Thomas Frisell (11 shared papers)Anders Svenningsson (6 shared papers)Jonatan Salzer (6 shared papers)Annette Magdalene Langer-Gould (5 shared papers)Joachim Burman (4 shared papers)
- Journals
- Annals of Neurology (5 papers)Neurology (2 papers)Multiple Sclerosis Journal (2 papers)Basic & Clinical Pharmacology & Toxicology (1 paper)European Journal of Epidemiology (1 paper)
- Partner nations
- SwedenUnited StatesGermany
In The Last Decade
Peter Alping
13 papers receiving 1.1k citations
Peter Alping's Hit Papers
Peers
Comparison fields: 5 of 59
- Pathology and Forensic Medicine 968
- Infectious Diseases 82
- Toxicology 15
- Neurology 35
- Immunology 26
Countries citing papers authored by Peter Alping
This map shows the geographic impact of Peter Alping's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Alping with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Alping more than expected).
Fields of papers citing papers by Peter Alping
This network shows the impact of papers produced by Peter Alping. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Alping. The network helps show where Peter Alping may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter Alping, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies Hit paper breakdown → | 2019 | 425 |
| 2 | Rituximab in multiple sclerosis Hit paper breakdown → | 2016 | 292 |
| 3 | 2016 | 193 | |
| 4 | 2020 | 112 | |
| 5 | 2018 | 55 | |
| 6 | 2021 | 17 | |
| 7 | 2024 | 13 | |
| 8 | 2023 | 9 | |
| 9 | 2024 | 9 | |
| 10 | 2024 | 8 | |
| 11 | 2025 | 5 | |
| 12 | 2023 | 4 | |
| 13 | Superior efficacy and tolerability of rituximab as compared to fingolimod for MS patients switching from natalizumab due to positive JC virus serology | 2015 | 2 |
About Peter Alping
Peter Alping is a scholar working on Pathology and Forensic Medicine, Public Health, Environmental and Occupational Health, Nuclear Energy and Engineering, Waste Management and Disposal and Infectious Diseases, having authored 13 papers that have together received 1.1k indexed citations. Recurring topics across this work include Multiple Sclerosis Research Studies (12 papers) and Pregnancy and Medication Impact (1 paper). The work is most often cited by research in Pathology and Forensic Medicine (968 citations), Infectious Diseases (82 citations), Toxicology (15 citations), Neurology (35 citations) and Immunology (26 citations). Peter Alping has collaborated with scholars based in Sweden, United States and Germany. Frequent co-authors include Fredrik Piehl, Jan Lycke, Katharina Fink, Thomas Frisell, Anders Svenningsson, Jonatan Salzer, Annette Magdalene Langer-Gould, Joachim Burman, Lenka Novakova and Markus Axelsson. Their work appears in journals such as Annals of Neurology, Neurology, Multiple Sclerosis Journal, Basic & Clinical Pharmacology & Toxicology and European Journal of Epidemiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.